Dr. Zhaohua Chang, aged 62. Dr. Chang has over 34 years’ experience in the medicaldevice industry, and currently serves as the chairman, executive director and chief executive officer of MicroPort Scientific Corporation (“MPSC”) (a controlling shareholder of the Company and a company listed on The Stock Exchange of Hong Kong Limited (the “Stock Exchange”), stock code: 00853), the chairman of the board and the non-executive director of MicroPort NeuroScientific Corporation (a company listed on the Stock Exchange, stock code: 02172) and a professor at School of Medical Device, University of Shanghai for Science and Technology. Before establishing Shanghai MicroPort Medical (Group) Co., Ltd. (上海微創醫療器械(集團)有限公司) in 1998, from 1996 to 1997, Dr. Chang served as vice president of R&D at Endocare Inc., a NASDAQ listed medical device company based in California, U.S.. From 1990 to 1995, Dr. Chang served as senior engineer, chief scientist, director of R&D and vice president of Engineering at Cryomedical Sciences Inc., a public medical device company in Maryland U.S..

Dr. Chang received his bachelor’s degree in refrigeration engineering in 1983 and master’s degree in cryogenic engineering in 1985, both from University of Shanghai for Science and Technology and received his doctoral degree in biological science from State University of New York (Binghamton) in 1992. Dr. Chang has published extensively in biomedical fields and holds several dozens of patents in the United States and in China.

Mr. Hiroshi Shirafuji, aged 81. Mr. Shirafuji served as a non-executive director of MPSC from November 2006 to June 2020 and from June 2023 to September 2025, and currently serves as the advisor of MPSC. Mr. Shirafuji was an executive director of Otsuka Medical Devices Co., Ltd. (“OMD”) from January 2017 to March 2017. From February 2011 to January 2017, he served as the president and representative director of OMD.Prior to joining OMD in February 2011, he was an executive director responsible for pharmaceuticals marketing at Otsuka Pharmaceutical Co., Ltd. (“Otsuka Pharmaceutical”) from 1997 to 1998. Mr. Shirafuji joined Otsuka Pharmaceutical in 1967.

Mr. Shirafuji received his bachelor’s degree in economics from Doshisha University in Kyoto in 1967.

Mr. Norihiro Ashida, aged 70. Mr. Ashida served as a non-executive director of MPSC from November 2006 to September 2025, and currently serves as the advisor of MPSC. Mr. Ashida was appointed as audit and supervisory board member of Cuorips Inc. (a company listed on the Tokyo Stock Exchange, stock code: 4894) with effect from 1 July 2024. Mr. Ashida has served as a director of J-Pharma Co., Ltd. since June 2021. From February 2011 to June 2022, Mr. Ashida successively served as a director and advisor of Otsuka Medical Devices, a subsidiary of Otsuka Holdings Co., Ltd. (“Otsuka Holdings”). Mr. Ashida was an executive operating officer of Otsuka Holdings and the director of its business development and planning department until 2015. Before joining Otsuka Pharmaceutical in April 2003, he was a general manager of Mizuho Corporate Bank Ltd. from 2002 to 2003. From 1999 to 2002, Mr. Ashida was a general manager of the Industrial Bank of Japan (“IBJ”), where he headed the credit department for western Japan. From 1995 to 1999, Mr. Ashida served as vice president responsible for business development at 3iBJ Ltd., a venture capital firm formed by 3i Group plc and IBJ. From 1989 to 1995, Mr. Ashida was a senior vice president of IBJ (Canada). He joined IBJ in 1977 in its Tokyo branch.

Mr. Ashida received his bachelor’s degree in economics from the University of Tokyo in 1977.

Mr. Chen Chen is the non-executive director of the Company, and is primarily responsible for overseeing the management and operations of the Group.

Mr. Chen Chen has 12 years of experience in the business consulting and investment management industry. From July 2015 to December 2018, Mr. Chen Chen worked at Shanghai Panxin Equity Investment Management Limited (上海盤信股權投資管理有限公司) where he held various positions, including investment manager, senior investment manager and vice president. From January 2019 to September 2020, he served as a principal at Tianjin Panmao Enterprise Management Limited Liability Partnership (天津盤茂企業管理合夥企業(有限合夥)). Since September 2020, he has successively served as a principal and executive general manager at Beijing Panmao Investment Management Co., Ltd. (北京盤茂投資管理有限公司) (‘‘CPE’’). Prior to joining the investment management industry, Mr. Chen Chen was a consultant at the Shanghai branch of Bain & Company from October 2009 to August 2013.

Mr. Chen Chen is currently also serving as a director of several other companies, including, a non-executive director of Shanghai Hanyu Medical Technology Co., Ltd. (上海捍宇醫療科技股份 有限公司), a director of Spectrum Dynamics Medical Group Limited and was a non-executive director of Acotec Scientific Holdings Limited (先瑞達醫療科技控股有限公司) from December 2020 to February 2023.

Mr. Chen Chen graduated from Shanghai Jiao Tong University in the PRC with a bachelor’s degree in electronic engineering in July 2005. He received his first master’s degree in industry economics from Shanghai Jiao Tong University in the PRC in March 2009, and his second master’s degree in business administration from University of Chicago in the United States in June 2015.

Ms. Min Liang, aged 39. Ms. Liang joined MicroPort Sinica Co., Ltd. in April 2021 and is currently the business director of its overseas business department. Since November 2023, Ms. Liang serves as the chairwoman of the board of supervisors of Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (上海微創心脈醫療科技(集團)股份有限公司 (a company listed on the Shanghai Stock Exchange, stock code: 688016). Prior to that,Ms. Liang was a marketing manager of Abbott Laboratories Trading (Shanghai) Co., Ltd. (雅培醫療器械貿易(上海)有限公司) from April 2011 to April 2021, and a senior sales representative of Johnson & Johnson Medical (China) Ltd. (強生(中國)醫療器材有限公司) from July 2008 to March 2011.

Ms. Liang holds a bachelor’s degree from Department of Chemistry, Fudan University and a master’s degree in global executive master of business administration (Global EMBA) from China Europe International Business School.

Dr. Chao He is the executive director and the president of the Company, and is mainly responsible for overseeing the research and development and day-to-day management and strategic development of the Group. He is also a member of the Nomination Committee and the Strategy and Development Committee.

Dr. Chao He has over 15 years of experience in the research and development of surgical robots. He joined the Group as the general manager of the Company in May 2015 and has been serving as the president since December 2020, primarily responsible for the business operations of the Company. Dr. He Chao also holds various directorships and management positions in the Group companies, including but not limited to the executive director of Suzhou MicroPort OrthoBot Co,. Ltd. (蘇州微創暢行機器人有限公司) (‘‘OrthoBot Suzhou’’) since July 2019, the representative of the Beijing branch of the Company since November 2020 and the representative of the Shanghai branch of OrthoBot Suzhou since July 2022.

Prior to joining the Group, from June 2013 to April 2014, Dr. He Chao served as the system engineer of Chinese Academy of Space Technology (中國空間技術研究院), a spacecraft designer and manufacturer, where he was mainly responsible for system engineering and project management. From April 2014 to May 2015, Dr. He Chao served as the senior director of Shanghai MicroPort Medical (Group) Co., Ltd. (上海微創醫療器械(集團)有限公司) (‘‘Shanghai MicroPort’’), a medical device manufacturer and an indirect wholly-owned subsidiary of the MicroPort, where he was primarily responsible for R&D and project management of surgical robots.

Dr. Chao He serves as the Chinese representative in the technical committee for the preparation of international technical standards for surgical robots of International Electrotechnical Commission, a global organization which builds international standards and conformity assessment systems to ensure the safety, efficiency, reliability and interoperability of electrical, electronic and information technologies. He is also a member of the first expert panel of China’s medical robot technical standardization unit and the director of Shanghai Engineering Research Center of Minimally Invasive Surgical Robots (上海微創手術機器人工程技術研究中心) sponsored by the Science and Technology Commission of Shanghai Municipality (上海市科學技術委員會).

Dr. Chao He graduated from Hefei University of Technology in the PRC with a bachelor’s degree in mechanical and electronics in July 2007 and graduated from Tianjin University in the PRC with a doctor’s degree in mechanical engineering in January 2014. During his Ph.D. study at Tianjin University, Dr. He Chao spent the 2011-12 academic year at Johns Hopkins University inthe United States as a visiting scholar.

Mr. Yu Liu, aged 52, joined the Group as Chief Commercial Officer and Vice President on 1 December 2020. Mr. Liu served as the Chief Commercial Officer and Senior Vice President of the Group from March 2021 to May 2022 and as the Commercial Officer and Executive Vice President of the Group from 1 June 2022, with primary responsibility for sales and marketing as well as clinical and medical affairs. He has also been serving as the executive director and manager of 1.1 Medical, since September 2020, where he is primarily responsible for its operations and management.

Mr. Liu has over 29 years of experience in pharmaceuticals and medical devices. Mr Liu joined Beijing office of American Medtronic China Co., Ltd. (美國美敦力中國有限責任公司北京辦事處), a medical technology company, in November 2001. In April 2003, Mr. Liu joined Chindex (Beijing) International Trade Co., Ltd. (美中互利北京國際貿易有限公司) (“Chindex Beijing”), a company principally engaged in provision of medical and health services and distribution of medical devices, as a north regional manager, where he was primarily responsible for product management. Mr. Liu then worked as the sales manager of Beijing office of Germany BrainLAB Co., Ltd. (德國博醫來公司北京代表處), a company principally engaged in surgical software and hardware development, until October 2006 where he was primarily responsible for its marketing and sales. He also served as the chief representative of the Beijing branch of Canadian IMRIS Co., Ltd. (加拿大醫美瑞有限公司北京代表處), a company principally engaged in medical device management, where he was primarily responsible for overseeing its daily operation. From July 2008 to 2017, Mr. Liu served as chief operating officer and senior vice president of Chindex Beijing and Chindex Medical Limited (美中互利醫療有限公司), a distribution partner for Intuitive Surgical’s da Vinci Surgical Systems in China. From January 2017 to August 2019, Mr. Liu successively served as a senior vice president and chief operation officer of the medical device department of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (上海復星醫藥（集團）股份有限公司), a pharmaceutical company whose shares are listed on the Stock Exchange (stock code: 2196), and a senior vice president and chief commercial officer of Intuitive Surgical-Fosun Medical Technology (Shanghai) Co., Ltd. (直觀復星醫療器械技術(上海)有限公司), a company principally engaged in medical device industry, where Mr. Liu was primarily responsible for managing the sales and marketing of its da Vinci surgical robot. From September 2019 to June 2020, he served as the chief executive officer of Shanghai Ruidao Medical Technology Co., Ltd. (上海睿刀醫療科技有限公司), a company principally engaged in production of medical devices, where he was primarily responsible for its overall operations and management.

Mr. Liu obtained a bachelor’s degree in mechanical instruments engineering from the Tianjin University of Technology (天津理工大學) in the PRC in 1992 and a master’s degree in economic management from Tsinghua University (清華大學) in the PRC.

Dr. Guoen Liu, aged 68. Dr. Liu was appointed as an independent non-executive director of MPSC on 3 September 2010. Dr. Liu is a noted scholar in the fields of health and development economics, health reform and pharmaceutical economics. Dr. Liu currently serves as Dean of Peking University Institute for Global Health and Development, MOE Yangtze River Scholar distinguished professor of economics at the Peking University National School of Development. From 2000 to 2006, Dr. Liu served as a tenured associate professor of University of North Carolina at Chapel Hill. From 1994 to 2000, Dr. Liu was assistant professor of University of Southern California. Dr. Liu also serves as editor or associate editor in various domestic and international academic journals in the field of health economics and pharmaceutical economics. From February 2021 to July 2024, Dr. Liu was an independent director of SciClone Pharmaceuticals (Holdings) Limited (賽生藥業控股有限公司, a company listed on the Stock Exchange, stock code: 06600, and the listing of its shares was withdrawn with effect from 5 July 2024). Dr. Liu is currently an independent director of Yunnan Baiyao Group Co., Ltd. (雲南白藥集團股份有限公司, a company listed on Shenzhen Stock Exchange (stock code: 000538)).

Dr. Liu received his bachelor’s degree in mathematics from Southwest Minzu University in 1981, his master’s degree in statistics from Southwestern University of Finance and Economics in 1985, his Ph.D. in economics from the City University of New York Graduate Center in 1991, and completed postdoctoral studies in health economics from Harvard University in 1994.

Mr. Jonathan H. Chou, aged 61. Mr. Chou was appointed as an independent non-executive director of MPSC on 3 September 2010. He is a seasoned finance executive and advisor with over 30 years of international experience across the semiconductor, electronics and industrial sectors. Mr. Chou was most recently the chief financial officer of UTAC Holdings Ltd., a global semiconductor assembly and test services provider, where he also oversaw the group’s information technology and human resources functions.

Prior to that, he served as chief financial officer of Kulicke & Soffa Industries, Inc. (Nasdaq: KLIC), a leading provider of semiconductor packaging and electronic assembly solutions, and concurrently held the position of interim chief executive officer from 2015 to 2016. During his tenure, he was also responsible for the company’s global IT and facilities operations. Earlier in his career, he held senior finance leadership roles with multinational corporations including Honeywell, Tyco ADT, Lucent Technologies Bell Labs, and Public Service Enterprise Group.

Mr. Chou currently serves as an independent non-executive director of MicroPort CardioFlow Medtech Corporation (a company listed on the Stock Exchange, stock code: 02160). He is also chairman of the board of the Emerging Markets Investors Alliance, a not-for-profit organization promoting sustainable governance among institutional investors, and advises several private-equity-backed companies including AddVita Pte. Ltd., an Asian healthcare distribution platform backed by SeaTown (a Temasek-linked fund).

Mr. Chou holds a MBA from Duke University’s Fuqua School of Business and a B.A. in Economics from the University at Buffalo. He has served since 2013 on the East Asia Regional Advisory Board of Duke University’s Fuqua School of Business.

Mr. Yao Haisong is the independent non-executive director of the Company. He is also the chairperson of the Nomination Committee and a member of the Remuneration and Appraisal Committee.

From March 2002 to June 2004, Mr. Yao Haisong served as an assistant researcher, legal manager and secretary to the chairman of the board of directors of Shanghai Biochip Co., Ltd. (上海生物芯片有限公司), a biotech company, where he was primarily responsible for research and legal matters.

Mr. Yao Haisong has over 15 years of working experience in law firms. Since July 2004, Mr. Yao has been serving as a practicing lawyer, and he later served as a partner of Shanghai Huzhong Law Firm (上海市滬中律師事務所), where he was primarily responsible for providing legal advice. From July 2011 to February 2015, he served as a practising lawyer and patent attorney of the Beijing Yingke (Shanghai) Law Firm (北京盈科(上海)律師事務所). Since February 2015, Mr. Yao Haisong has been serving as a practising lawyer and partner of Shanghai Tianhua Law Firm (上海市天華律師事務所), where he was primarily responsible for providing business related legal advice.

Mr. Yao Haisong graduated from Shanghai Second Medical University in the PRC with a bachelor’s degree in clinical medicine in July 2000. He received a second bachelor’s degree in jurisprudence from Shanghai University in the PRC in July 2002, and his master’s degree in international business law from National University of Singapore in Singapore in June 2008. Mr. Yao Haisong is currently serving as a part-time researcher of Intelligent Medicine Institute, Fudan University (復旦大學智能醫學研究院), a member of China Research Hospital Association Clinical Data and Bio-bank a standing committee member (中國研究型醫院學會臨床數據與樣本資源庫專業委員會), a committee member of National Technical Committee on Bio-specimen of Standardization Administration of China (全國生物樣本標準化技術委員會) (SAC/TC559).

Mr. Wai Man Chung (鍾偉文), aged 60, has over 30 years of experience in accounting,taxation and corporate finance.

Mr. Chung obtained a bachelor’s degree in social sciences from The University of Hong Kong in December 1989 and a master’s degree in international business management from City University of Hong Kong in November 1998. Mr. Chung has been an associate member of the Hong Kong Institute of Certified Public Accountants since April 1995 and a fellow of The Association of Chartered Certified Accountants in the United Kingdom since November 1999.

Mr. Chung has served as an independent non-executive director of Net Pacific Financial Holdings Limited (listed on the Singapore Exchange Limited (stock code: 5QY)) since June 2018, E Lighting Group Holdings Limited (listed on the Stock Exchange (stock code: 8222)) since September 2014 and Shandong Fengxiang Co., Ltd (listed on the Stock Exchange (stock code: 9977)) since August 2019.